TXG Stock Recent News

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

10x Genomics reported impressive Q2 performance with revenue growing by 28% YoY to reach $147M. The company's growth is driven by strong performance in both single-cell and spatial biology portfolios. Despite challenges in the Chinese market and a decrease in gross margin, 10x Genomics remains well-positioned for growth with a strong cash position.

While the top- and bottom-line numbers for 10x Genomics (TXG) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

10x Genomics (TXG) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.57 per share a year ago.

Fintel reports that on July 13, 2023, Goldman Sachs maintained coverage of 10x Genomics Inc – (TXG) with a Sell recommendation.

10x Genomics has been on my Compounding Healthcare “Bio Boom” speculative portfolio watch list since its IPO back in 2019. I believe 10x Genomics is becoming an entrenched name. After performing some analysis, I believe the company's growth record and prospects outweigh the risks at this point. I am moving it up on my watch list. The medicines of the future will rely upon the technology that 10x is involved in. Clearly, this could lead to a massive market opportunity for the company.

On May 23, 2023, Serge Saxonov, CEO of 10x Genomics Inc ( TXG , Financial), sold 2,602 shares of the company's stock. This insider sell comes amidst a year of insider transactions that have seen Saxonov sell a total of 15,934 shares and make no purchases.

It could be an inflection year for 10x Genomics, one analyst says. TXG stock bounded off a low in October and is now on a seven-month sprint.

10x Genomics develops cutting-edge platforms for single-cell and spatial analysis, driving advances in disease research and drug discovery. Despite market fluctuations, their strong product pipeline is expected to fuel revenue growth and expand their customer base.

PLEASANTON, Calif. , Feb. 22, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming 43rd Annual Cowen Healthcare Conference in Boston, Massachusetts.